Skip to main content

Table 1 Canakinumab doses by phenotypes

From: Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients

Phenotype (n=WP/JP)

Wester population

Japanese population

 

Adult1 Mean/median (mg) (N=136)

Pediatrics2 Mean/mdeian (mg/kg) (N=29)

Adult1 Mean/median (mg) (N=8)

Pediatrics2 Mean/mdeian (mg/kg) (N=11)

MWS (103/7)

200/150

5.5/4.0

225/150

6.0/6.0

NOMID (32/11)

299/150

5.8/4.0

300/225

5.5/6.0

FCAS (30/0)

189/150

2.7/2.0

-

-